APO RESEARCH · REPORT
LFA-based Cardiac
Lateral Flow Assay is a simple to use diagnostic device used to confirm the presence or absence of a target analyte, such as pathogens or biomarkers in humans or animals, or contaminants in water supplies, foodstuffs, or animal feeds.
Product & engineering
Understand the product.
Lateral Flow Assay is a simple to use diagnostic device used to confirm the presence or absence of a target analyte, such as pathogens or biomarkers in humans or animals, or contaminants in water supplies, foodstuffs, or animal feeds.
Cardiac biomarkers are the substances released into the blood stream from the damaged muscle of the heart. These biomarkers are used to diagnose heart functioning, risk stratifications, and cardiac diseases in patients. Biomarker is a quantifiable and measurable biological parameter that includes an enzyme, hormones, and proteins, all associated with heart function, failure, or damage.
Selected research
Industry Growth & Trends
Global LFA-based Cardiac Industry Growth and Trends Forecast to 2032
Market perspective
Lateral Flow Assay is a simple to use diagnostic device used to confirm the presence or absence of a target analyte, such as pathogens or biomarkers in humans or animals, or contaminants in water supplies, foodstuffs, or animal feeds.
Cardiac biomarkers are the substances released into the blood stream from the damaged muscle of the heart. These biomarkers are used to diagnose heart functioning, risk stratifications, and cardiac diseases in patients. Biomarker is a quantifiable and measurable biological parameter that includes an enzyme, hormones, and proteins, all associated with heart function, failure, or damage.
According to APO Research, the global LFA-based Cardiac market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
Read the full market overview
Report Scope
This report provides a structured, data-driven view of the global LFA-based Cardiac market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The LFA-based Cardiac market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global LFA-based Cardiac market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to LFA-based Cardiac.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global LFA-based Cardiac market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
LFA-based Cardiac Market by Company
Roche
Abbott
Siemens
Danaher
Bio-Rad Laboratories
BioMérieux
Thermo Fisher
Ortho Clinical Diagnostics
LSI Medience Corporation
Randox laboratories
Wondfo Biotech
LFA-based Cardiac Segment by Type
Troponin I
Troponin T
CK-MB
Myoglobin
Others
LFA-based Cardiac Segment by Application
Laboratory Testing
Point-of-care Testing
LFA-based Cardiac Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global LFA-based Cardiac market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of LFA-based Cardiac and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of LFA-based Cardiac.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of LFA-based Cardiac companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Troponin I
- Troponin T
- CK-MB
- Myoglobin
- Others
Applications
- Laboratory Testing
- Point-of-care Testing
Companies covered
- Roche
- Abbott
- Siemens
- Danaher
- Bio-Rad Laboratories
- BioMérieux
- Thermo Fisher
- Ortho Clinical Diagnostics
- LSI Medience Corporation
- Randox laboratories
- Wondfo Biotech
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global LFA-based Cardiac Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global LFA-based Cardiac Market Size by Region (2021-2032)
- 1.4.1 Global LFA-based Cardiac Market Size by Region (2021-2026)
- 1.4.2 Global LFA-based Cardiac Market Size by Region (2027-2032)
- 1.5 Key Regions LFA-based Cardiac Market Size (2021-2032)
- 1.5.1 North America LFA-based Cardiac Market Size Growth Rate (2021-2032)
- 1.5.2 Europe LFA-based Cardiac Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific LFA-based Cardiac Market Size Growth Rate (2021-2032)
- 1.5.4 South America LFA-based Cardiac Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa LFA-based Cardiac Market Size Growth Rate (2021-2032)
2 LFA-based Cardiac Market by Type
- 2.1 Type Introduction
- 2.1.1 Troponin I
- 2.1.2 Troponin T
- 2.1.3 CK-MB
- 2.1.4 Myoglobin
- 2.1.5 Others
- 2.2 Global LFA-based Cardiac Market Size by Type
- 2.2.1 Global LFA-based Cardiac Market Size Overview by Type (2021-2032)
- 2.2.2 Global LFA-based Cardiac Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global LFA-based Cardiac Market Size Forecasted by Type (2027-2032)
- 2.3 Global LFA-based Cardiac Market Size by Regions
- 2.3.1 North America LFA-based Cardiac Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe LFA-based Cardiac Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific LFA-based Cardiac Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America LFA-based Cardiac Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa LFA-based Cardiac Market Size Breakdown by Type (2021-2026)
3 LFA-based Cardiac Market by Application
- 3.1 Type Introduction
- 3.1.1 Laboratory Testing
- 3.1.2 Point-of-care Testing
- 3.2 Global LFA-based Cardiac Market Size by Application
- 3.2.1 Global LFA-based Cardiac Market Size Overview by Application (2021-2032)
- 3.2.2 Global LFA-based Cardiac Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global LFA-based Cardiac Market Size Forecasted by Application (2027-2032)
- 3.3 Global LFA-based Cardiac Market Size by Regions
- 3.3.1 North America LFA-based Cardiac Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe LFA-based Cardiac Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific LFA-based Cardiac Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America LFA-based Cardiac Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa LFA-based Cardiac Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 LFA-based Cardiac Industry Trends
- 4.2 LFA-based Cardiac Industry Drivers
- 4.3 LFA-based Cardiac Industry Opportunities and Challenges
- 4.4 LFA-based Cardiac Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by LFA-based Cardiac Revenue (2021-2026)
- 5.2 Global LFA-based Cardiac Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global LFA-based Cardiac Key Company Headquarters & Area Served
- 5.4 Global LFA-based Cardiac Company, Product Type & Application
- 5.5 Global LFA-based Cardiac Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global LFA-based Cardiac Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 LFA-based Cardiac Players Market Share by Revenue in 2025
- 5.6.3 2025 LFA-based Cardiac Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Roche
- 6.1.1 Roche Company Information
- 6.1.2 Roche Business Overview
- 6.1.3 Roche LFA-based Cardiac Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Roche LFA-based Cardiac Product Portfolio
- 6.1.5 Roche Recent Developments
- 6.2 Abbott
- 6.2.1 Abbott Company Information
- 6.2.2 Abbott Business Overview
- 6.2.3 Abbott LFA-based Cardiac Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Abbott LFA-based Cardiac Product Portfolio
- 6.2.5 Abbott Recent Developments
- 6.3 Siemens
- 6.3.1 Siemens Company Information
- 6.3.2 Siemens Business Overview
- 6.3.3 Siemens LFA-based Cardiac Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Siemens LFA-based Cardiac Product Portfolio
- 6.3.5 Siemens Recent Developments
- 6.4 Danaher
- 6.4.1 Danaher Company Information
- 6.4.2 Danaher Business Overview
- 6.4.3 Danaher LFA-based Cardiac Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Danaher LFA-based Cardiac Product Portfolio
- 6.4.5 Danaher Recent Developments
- 6.5 Bio-Rad Laboratories
- 6.5.1 Bio-Rad Laboratories Company Information
- 6.5.2 Bio-Rad Laboratories Business Overview
- 6.5.3 Bio-Rad Laboratories LFA-based Cardiac Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Bio-Rad Laboratories LFA-based Cardiac Product Portfolio
- 6.5.5 Bio-Rad Laboratories Recent Developments
- 6.6 BioMérieux
- 6.6.1 BioMérieux Company Information
- 6.6.2 BioMérieux Business Overview
- 6.6.3 BioMérieux LFA-based Cardiac Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 BioMérieux LFA-based Cardiac Product Portfolio
- 6.6.5 BioMérieux Recent Developments
- 6.7 Thermo Fisher
- 6.7.1 Thermo Fisher Company Information
- 6.7.2 Thermo Fisher Business Overview
- 6.7.3 Thermo Fisher LFA-based Cardiac Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Thermo Fisher LFA-based Cardiac Product Portfolio
- 6.7.5 Thermo Fisher Recent Developments
- 6.8 Ortho Clinical Diagnostics
- 6.8.1 Ortho Clinical Diagnostics Company Information
- 6.8.2 Ortho Clinical Diagnostics Business Overview
- 6.8.3 Ortho Clinical Diagnostics LFA-based Cardiac Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Ortho Clinical Diagnostics LFA-based Cardiac Product Portfolio
- 6.8.5 Ortho Clinical Diagnostics Recent Developments
- 6.9 LSI Medience Corporation
- 6.9.1 LSI Medience Corporation Company Information
- 6.9.2 LSI Medience Corporation Business Overview
- 6.9.3 LSI Medience Corporation LFA-based Cardiac Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 LSI Medience Corporation LFA-based Cardiac Product Portfolio
- 6.9.5 LSI Medience Corporation Recent Developments
- 6.10 Randox laboratories
- 6.10.1 Randox laboratories Company Information
- 6.10.2 Randox laboratories Business Overview
- 6.10.3 Randox laboratories LFA-based Cardiac Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Randox laboratories LFA-based Cardiac Product Portfolio
- 6.10.5 Randox laboratories Recent Developments
- 6.11 Wondfo Biotech
- 6.11.1 Wondfo Biotech Company Information
- 6.11.2 Wondfo Biotech Business Overview
- 6.11.3 Wondfo Biotech LFA-based Cardiac Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Wondfo Biotech LFA-based Cardiac Product Portfolio
- 6.11.5 Wondfo Biotech Recent Developments
7 North America
- 7.1 North America LFA-based Cardiac Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America LFA-based Cardiac Market Size by Country (2021-2026)
- 7.3 North America LFA-based Cardiac Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe LFA-based Cardiac Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe LFA-based Cardiac Market Size by Country (2021-2026)
- 8.3 Europe LFA-based Cardiac Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific LFA-based Cardiac Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific LFA-based Cardiac Market Size by Country (2021-2026)
- 9.3 Asia-Pacific LFA-based Cardiac Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America LFA-based Cardiac Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America LFA-based Cardiac Market Size by Country (2021-2026)
- 10.3 South America LFA-based Cardiac Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa LFA-based Cardiac Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa LFA-based Cardiac Market Size by Country (2021-2026)
- 11.3 Middle East & Africa LFA-based Cardiac Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst